Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-017-0511-y
Abstract: Parkinson’s disease (PD) is a chronic progressive neurological disorder characterized by resting tremor, rigidity, bradykinesia, gait disturbance, and postural instability. Levodopa, the precursor to dopamine, coadministered with carbidopa or benserazide, aromatic amino acid decarboxylase inhibitors,… read more here.
Keywords: release; carbidopa levodopa; capsule formulation; levodopa ... See more keywords
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the Neurological Sciences"
DOI: 10.1016/j.jns.2016.11.047
Abstract: BACKGROUND IPX066 (Rytary®; carbidopa and levodopa [CD-LD] extended-release capsules) was designed to achieve therapeutic LD plasma concentrations within 1h of dosing and maintain LD concentrations for a prolonged duration in early or advanced Parkinson's disease… read more here.
Keywords: carbidopa levodopa; ipx066; conversion; release ... See more keywords
Outpatient titration of carbidopa/levodopa enteral suspension (Duopa)
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Neuroscience"
DOI: 10.1080/00207454.2016.1193862
Abstract: Carbidopa/levodopa enteral suspension (CLES; Duopa) is a suspension or gel formulation of carbidopa/levodopa that is approved by the USA Food and Drug Administration for the treatment of advanced Parkinson's disease patients with motor fluctuations. CLES… read more here.
Keywords: pump; carbidopa levodopa; levodopa enteral; enteral suspension ... See more keywords